Follow us on:

Linkedin Facebook

ImmuPharma PLC Lupuzor™ Pivotal Phase III Study Update

Immupharma plc
[shareaholic app="share_buttons" id_name="post_below_content"]

ImmuPharma PLC (LON:IMM), the specialist drug discovery and development company announces that it has been informed by Simbec-Orion, the contract research organisation conducting our Lupuzor™ pivotal Phase III trial study, that ‘database lock’ is expected on 6 April 2018, with top line results announced by mid-April 2018.

Lupuzor™ is the Company’s lead programme for the potential breakthrough compound for Lupus, a life threatening autoimmune disease.

Commenting on the trial update, Tim McCarthy, ImmuPharma PLC Chairman, said: “With the continued robust safety record of Lupuzor™ achieved over this trial, we look forward with confidence to reporting top line results in the near future.”

We’ll keep you in the loop!

Join 1,000's of investors who read our articles first

We don’t spam! Read our privacy policy for more info.

Twitter
LinkedIn
Facebook
Email
Reddit
Telegram
WhatsApp
Pocket
Find more news, interviews, share price & company profile here for:

    Latest Company News

    immunodiagnostics

    ImmuPharma two specialist US healthcare investments of up to $6.30 million

    52 Grosvenor Garden, London SW1W 0AU

    ImmuPharma AGM Venue to be held at Grosvenor Garden

    Broker Ratings

    Market Risers: 3i Group plc, Hargreaves Lansdown, ImmuPharma, Marks and Spencer Group

    Peptides COVID

    ImmuPharma’s efforts in the fight against Covid-19 with Lupuzor™ and Ureka

    Broker Ratings

    Market Risers: Hargreaves Lansdown, ImmuPharma, ITV

    Broker Ratings

    Market Risers: ImmuPharma, International Consolidated Airlines Group, ITV, KEFI Minerals

      Latest interviews

      View all interviews 

      Company Presentations

      View all Company Presentations

      Brokers Talk

      View all Broker Talk

      FTSE 100 News

      Search

      Search

      Green News

      View all Sustainable sectors, Plcs and news  

      Q&A's

      View all Question and Answers

      Funds

      View all Funds, Market Insights and news

      UK Broker Ratings

      Hardman & Co

      Don't Miss Our News Alerts

      Subscribe Free

      Find us on:

      Linkedin Facebook

      Useful links

      Disclaimer

      You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular stock, share, security, portfolio of securities, transaction, investment strategy, or other matter. We openly disclose that we and our contributors may have interests in investments and/or providers of services referred to within the website and that we receive remuneration from certain of the companies referred to on this website.

      © 2024 – DirectorsTalk Interviews. All rights reserved. Reproduction in whole or in part, in any form or medium without express written permission is prohibited.